Pemgarda Q Code: Q0224

Pemgarda is a medication aligned to the HCPCS Q Code: Q0224 for billing, pricing, and reimbursement purposes in the United States. This Anti-Anemia medication is administered via the intravenous route and manufactured by Invivyd.

According to CMS Drug Use Information: Pemivibart is a medication that the FDA is allowing to be given for emergency use to reduce the risk of getting COVID-19 infection in people who do not have COVID-19 and who have not been exposed to anyone with COVID-19. To receive this product, you must also have a weakened immune system because of certain conditions or medications (such as cancer, transplant), which reduces your response to the COVID-19 vaccine. It does not replace the COVID-19 vaccines. Talk to your doctor about the risks and benefits of treatment with pemivibart. This medication belongs to a class of drugs known as monoclonal antibodies. It works by preventing the COVID-19 virus from entering the cells in the body. This effect may prevent COVID-19. More information about pemivibart is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use provided by your health care professional. If you are enrolled in a study, information should be provided by the doctor via the Informed Consent Form. There is limited information about how safe and effective pemivibart is for preventing COVID-19. This medication should not be used to treat COVID-19 or in people who have already been exposed to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of pemivibart, and it is always the responsibility of treating practitioners to exercise independent judgment in making care decisions.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.